Molecular alterations and clinical prognostic factors in resectable non-small cell lung cancer

EGFR inhibitor and immunotherapy have been approved for adjuvant treatment in resectable nonsmall cell lung cancer (NSCLC). Limited reports of molecular and clinical characteristics as prognostic factors in NSCLC have been published.